ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Clinical trials for ESOPHAGEAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ESOPHAGEAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a new infusion drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis early-stage trial is testing an investigational drug called BL-ARC002 in people with advanced gastrointestinal or other solid tumors that have spread. The main goals are to find a safe dose and to see if the drug shows any signs of shrinking tumors. Participants receive the …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a new drug rally the immune system against Hard-to-Treat cancers?
Disease control Not yet recruitingThis early-stage trial tests an experimental medicine called BI 3822971 in adults with advanced or metastatic solid cancers, such as lung, head and neck, breast, esophageal, bladder, vulvar, or cervical cancer, who have no standard treatment options left. The goal is to find out …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Smart T-Cell engager aims to outsmart tumors in first human test
Disease control Not yet recruitingThis early-phase trial tests an experimental drug, KGX105, in people with advanced solid tumors that have not responded to standard treatments. KGX105 is designed to activate immune T-cells specifically within the tumor, potentially reducing side effects. The study will assess sa…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Kangabio AUSTRALIA LTD PTY • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Triple-Drug cocktail aims to tackle esophageal cancer that resists standard therapy
Disease control Not yet recruitingThis phase II trial tests a combination of three drugs—Becotatug Vedotin, Tislelizumab, and low-dose Lenvatinib—in people with advanced esophageal squamous cell carcinoma whose cancer has progressed after first-line therapy. The study aims to see if this triple therapy can shrink…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat esophageal tumors
Disease control Not yet recruitingThis phase II trial tests a new drug called SKB500 in combination with standard chemotherapy and immunotherapy for people with advanced esophageal squamous cell carcinoma that cannot be removed by surgery. The study will evaluate how well the combination shrinks tumors and how sa…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug cocktail targets tough esophageal cancer
Disease control Not yet recruitingThis trial tests a new drug called becotatug vedotin, given together with standard chemotherapy (cisplatin) and radiation, for people with a type of advanced esophageal cancer. The main goals are to find the safest dose and see how well the combination works. About 12 participant…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Tailored drug cocktails aim to outsmart resistant esophageal cancer
Disease control Not yet recruitingThis study tests whether matching drug combinations to a patient's tumor genetics can help when standard immunotherapy stops working. About 90 people with advanced esophageal cancer will get one of three treatment pairs based on their cancer's molecular profile. The goal is to se…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for hard-to-treat cancers? experimental combo enters phase 2 trial
Disease control Not yet recruitingThis study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: GV20 Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug combo shows promise in shrinking esophageal tumors before surgery
Disease control Not yet recruitingThis study tests whether adding a new drug called retlirafusp alfa to standard chemotherapy before surgery can help shrink tumors in people with a type of esophageal cancer. About 33 adults with locally advanced esophageal squamous cell carcinoma will receive the combination trea…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can a blood test guide better cancer treatment after surgery?
Disease control Not yet recruitingThis Phase 3 trial tests whether using a blood test that detects tumor DNA can guide who needs extra therapy after esophageal cancer surgery. Participants will either receive a combination of immunotherapy (tislelizumab), chemotherapy, and radiation, or be monitored without addit…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New immune drug takes on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called CRPA1A2, which helps the body's immune cells attack cancer cells. It is for people with certain advanced solid tumors (like lung, esophagus, head and neck, or liver cancer) that have not responded to other treatments. The study will …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Corregene Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail shows promise in shrinking esophageal tumors before surgery
Disease control Not yet recruitingThis phase 2 trial will test whether adding the experimental drug ivonescimab to standard chemotherapy before surgery can improve outcomes for people with resectable esophageal squamous cell carcinoma. About 49 participants will receive three cycles of the combination, then under…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail aims to shrink esophageal tumors before surgery
Disease control Not yet recruitingThis study tests whether a combination of three drugs (camrelizumab, chemotherapy, and ivarmacitinib) given before surgery can help people with a type of esophageal cancer. The goal is to see if the treatment can eliminate or shrink the tumor enough to improve surgical outcomes. …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New study tests if All-Keyhole surgery beats hybrid approach for esophageal cancer
Disease control Not yet recruitingThis phase 3 trial will compare two surgical techniques for esophageal cancer: totally minimally invasive esophagectomy (TMIE) using only keyhole incisions, versus a hybrid approach that combines keyhole and open chest surgery. The study aims to see if TMIE reduces severe complic…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Smart scan may personalize esophageal cancer therapy
Disease control Not yet recruitingThis phase II trial tests whether a special PET scan (FAPI-PET/CT) can help doctors choose the best treatment for people with resectable esophageal cancer. After two cycles of chemoimmunotherapy, the scan results will guide whether patients continue with more chemoimmunotherapy o…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Ji Yongling • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug may keep esophageal cancer from coming back after surgery
Disease control Not yet recruitingThis study tests whether the drug toripalimab, given after surgery, can help prevent esophageal cancer from returning in patients at high risk of recurrence. About 435 adults who have already had chemotherapy and immunotherapy before surgery will either receive toripalimab or be …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug cocktail shows promise for tough esophageal cancer
Disease control Not yet recruitingThis study tests a new drug called QL1706 combined with chemotherapy for people with a type of esophageal cancer that is hard to remove with surgery. The goal is to shrink the tumor enough so that surgery can be done successfully. 24 adults with this cancer will receive the drug …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for esophageal cancer: triple therapy enters major trial
Disease control Not yet recruitingThis study tests a new combination of drugs for people with advanced or metastatic esophageal squamous cell carcinoma who have not had prior treatment. The experimental therapy includes SYS6010 (a targeted antibody-drug conjugate) plus SG001 (an immunotherapy), with or without st…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New shot for tough esophageal cancer enters early human testing
Disease control Not yet recruitingThis early-stage study tests a new drug called IPM514 in 36 people with advanced esophageal cancer that cannot be removed by surgery or has spread. The drug is given as a shot, and the main goals are to check safety and find the best dose. Researchers will also look for early sig…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Beijing Immupeutics Medicine Technology Limited • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Glowing dye could guide safer cancer surgery
Diagnosis Not yet recruitingThis study tests whether a special dye, called indocyanine green, can help surgeons find cancer that has spread to nearby lymph nodes during esophageal cancer surgery. About 144 adults with esophageal cancer will take part. If the dye works well, it may allow doctors to remove fe…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Fujian Medical University Union Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 08:06 UTC
-
Could skipping the breathing tube make esophageal cancer surgery safer?
Symptom relief Not yet recruitingThis study tests whether using a laryngeal mask instead of a breathing tube during esophageal cancer surgery can reduce complications and speed up recovery. About 500 adults with resectable esophageal cancer will be randomly assigned to one of two anesthesia methods. The goal is …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: The First Affiliated Hospital of Guangzhou Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Scientists to map tumor changes after cancer combo therapy
Knowledge-focused Not yet recruitingThis study will look at tumor samples from 12 people with esophageal cancer before and after they receive standard chemotherapy plus immunotherapy followed by surgery. Using advanced techniques like single-cell analysis, researchers aim to understand how the tumor environment cha…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Sponsor: Nanjing Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
AI could revolutionize esophageal cancer care: 7,000-Patient study launches
Knowledge-focused Not yet recruitingThis study aims to develop an AI system that helps doctors choose the best treatment for esophageal cancer. Researchers will collect data from 7,000 patients, including medical images and tissue samples, to train a computer model that predicts how well a patient will respond to t…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Sponsor: Henan Cancer Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC